Based on the single-cell method, we explored whether EGFR activating mutation heterogeneity in a tumor did exist in actual lung adenocarcinoma specimens positive for the L858R mutation in exon 21 of EGFR and its relation to EGFR-TKI response. This evidence concerns the gene EGFR and neoplasm.